David Carling

This paper shows that loss-of-function variants in MAP3K7 cause dilated cardiomyopathy (DCM), both as part of syndromic disease and as apparently isolated DCM.

This paper identifies and functionally assesses GPCRs during human adipogenesis, revealing novel expression patterns and therapeutic targets.

This paper uses automated behavioural tracking in C. elegans to phenotype 25 disease models, revealing both strong and subtle mutant effects that could aid drug repurposing.

This study shows that inhibiting IL11 improves healthspan in aged mice by reversing metabolic dysfunction, sarcopenia, and frailty.

This study investigates the antitumour activity of CT7001, a CDK7 inhibitor, in castration-resistant prostate cancer models, showing it inhibits proliferation and enhances enzalutamide efficacy.

This study identifies IL11's role in inhibiting LKB1/AMPK and activating mTOR through ERK/P90RSK, leading to metabolic dysfunction and fibrosis in multiple cell types and NASH in mice.

The paper identifies mitochondrial defects in eliminated cells during early mouse development and shows that cell competition removes cells with mitochondrial DNA mutations and sequence changes.

The paper investigates IL11-driven fibrosis mechanisms, showing ERK, not STAT3, drives fibrogenesis and identifies a novel role for nintedanib in inhibiting pro-fibrotic translation.